BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives, and specialty products in China. The company's portfolio includes licorice-based pharmaceuticals and extracts such as Gan Di Xin, an antitussive and expectorant medicine, and Qilian Shan licorice extracts sold to pharmaceutical manufacturers. The company also produces oxytetracycline tablets and APIs for both human and veterinary applications, alongside heparin sodium preparations used in cardiovascular and hemodialysis treatments.
Beyond pharmaceuticals, BGM Group operates in adjacent product categories including traditional Chinese medicine products like the antibacterial paste Ahan, natural sausage casings, and organic and organic-inorganic compound fertilizers marketed under the Xiongguan brand for agricultural applications. This diversification across pharmaceuticals, traditional medicine, food ingredients, and agricultural products reflects a multi-segment business model serving pharmaceutical manufacturers, medical preparation companies, food producers, and agricultural customers.
The company operates with approximately 298 full-time employees and maintains headquarters in Chengdu, China. BGM Group was incorporated in the Cayman Islands in 2019 and is listed on Nasdaq. The company previously operated under the name Qilian International Holding Group Limited before rebranding to BGM Group Ltd in October 2024.
No 10-K filings found.